Navigation ▼

Stellenwert des Opioidantagonisten Naltrexon bei stationär behandelten Borderline-Patienten

Improvement of Borderline Personality Disorder with Naltrexone: Results of a retroperspective evaluation

Miriam Meiser
Doctoral thesis
Date of Examination: 2016-10-05
Date of issue: 2016-09-23
Advisor: Bandelow, Borwin Prof. Dr.
Referee: Bandelow, Borwin Prof. Dr.
Referee: Friede, Tim Prof. Dr.
Referee: Brockmöller, Jürgen Prof. Dr.

Persistent Address: http://hdl.handle.net/11858/00-1735-0000-002B-7C0B-D

 

Files in this item

Name: Dissertation Meiser.pdf
Size: 681,6 KB
Format: PDF
View/Open

The following license files are associated with this item:

Abstract

English

Introduction: Although 85% of inpatients with Borderline Personality Disorder (BPD) receive psychotropic drug treatment, no drug is approved for this indication so far. A dysregulation of the endogenous opioid system (EOS) has been posed to underly the neurobiology of BPD. Accordingly, the opioid antagonist naltrexone might be helpful to treat symptoms of BPD. Two small studies showed limited differences of naltrexone vs. placebo on dissociation, which were not significant, perhaps due to the low power of the studies. Methods: A retrospective analysis of the charts of inpatients (n=161) with BPD was performed. Patients were classified as either treatment responders or non-responders. As all patients received multiple psychopharmacological treatments, stepwise logistic regression analysis was performed to detect, which drug contributed most to improvement of symptomatology. Results: None of the drugs applied contributed significantly to improvement, with the exception of naltrexone (odds ratio, p=2,9) Patients treated with naltrexone (n=55, 34,16%) recovered significantly more often and faster and, in particular, showed highly significant reduction of self-harm and suicidal thoughts. Higher doses of naltrexone treatment were more effective than low-dose treatment; however, the latter was still better than any other treatment. Conclusion: Large-scale double-blind studies are warranted to examine the efficacy of opioid antagonists (naltrexone, nalmefene) in BPD.
Keywords: Borderline Personality Disorder; Naltrexone; endogenous opioid system; inpatients; Psychiatry
Schlagwörter: Borderline Persönlichkeitsstörung; Naltrexon; Opioidantagonist; EOS; Psychopharmakologie
View Statistics

This item appears in the following Collection(s)